MITF and breast carcinoma: Indeed, tissue microarray analyses in clinically annotated primary basal breast tumor samples (n = 45) validated MITF positivity in tumor cells and revealed a significant association between MITF expression and patient survival (P < 0.006, log-rank test), with median survival of 1208 and 2406 days for the positive and negative staining groups, respectively (see Kaplan–Meier survival curve and representative MITF-positive staining in basal breast cancer patients in Fig. 6a, b).